Dynavax Technologies (NASDAQ:DVAX) Rating Lowered to Sell at The Goldman Sachs Group

Dynavax Technologies (NASDAQ:DVAX) was downgraded by equities research analysts at The Goldman Sachs Group from a “neutral” rating to a “sell” rating in a note issued to investors on Tuesday,Finviz reports. They currently have a $12.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $15.00. The Goldman Sachs Group’s price target points to a potential downside of 9.09% from the stock’s current price.

DVAX has been the topic of several other reports. HC Wainwright increased their price objective on shares of Dynavax Technologies from $29.00 to $31.00 and gave the stock a “buy” rating in a report on Tuesday, January 14th. StockNews.com raised shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday, January 14th.

Dynavax Technologies Price Performance

Dynavax Technologies stock opened at $13.20 on Tuesday. Dynavax Technologies has a 52 week low of $9.74 and a 52 week high of $13.89. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. The firm’s 50-day simple moving average is $12.81 and its 200 day simple moving average is $11.90. The firm has a market capitalization of $1.74 billion, a PE ratio of 101.55 and a beta of 1.32.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of DVAX. Assenagon Asset Management S.A. acquired a new position in Dynavax Technologies during the third quarter worth about $8,291,000. PDT Partners LLC purchased a new position in Dynavax Technologies in the 3rd quarter worth about $3,967,000. Nordea Investment Management AB increased its stake in Dynavax Technologies by 42.7% in the 4th quarter. Nordea Investment Management AB now owns 777,816 shares of the biopharmaceutical company’s stock worth $10,034,000 after purchasing an additional 232,690 shares in the last quarter. Mizuho Markets Americas LLC increased its stake in Dynavax Technologies by 17.4% in the 3rd quarter. Mizuho Markets Americas LLC now owns 1,379,582 shares of the biopharmaceutical company’s stock worth $15,369,000 after purchasing an additional 204,475 shares in the last quarter. Finally, Barclays PLC increased its stake in Dynavax Technologies by 137.4% in the 3rd quarter. Barclays PLC now owns 302,572 shares of the biopharmaceutical company’s stock worth $3,371,000 after purchasing an additional 175,118 shares in the last quarter. 96.96% of the stock is owned by institutional investors and hedge funds.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.